ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities: ONS Biotherapy Phase II, Outcomes-Research Grant

August 3, 2001

Carbone to Give Up ECOG Chairmanship; DCE’s Adamson Receives Presidential Executive Award

October 6, 1989

New Diet Trial Is Described In Concept

October 26, 1990

Sprycell Approved for CML

November 5, 2010

Letter to the Editors: Researchers Must Keep Up NIH Advocacy Particularly Now

October 11, 1996

FDA news: Von Eschenbach to FDA staff: “I did not come here to be a figurehead…. While I am here, I will lead.”

November 4, 2005